Trial Profile
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMA
- Sponsors Novartis
- 16 Sep 2017 Results presented in a Novartis media release.
- 16 Sep 2017 According to a Novartis media release, data were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
- 27 Nov 2016 Status changed from active, no longer recruiting to completed.